Eurasian Medical Journal

International Higher School of Medicine

ISSN 1694-8254

Chemical pleurodesis using betadine and glucose in the treatment of patients with transudative pleural effusion in case of chronic kidney disease

A.A. Egay1, 2, B. Kh. Bebezov¹, A.T. Kazakbaev¹, A.E. Tentimishev², A.M. Feigin3

Abstract
Transudative pleural effusion (PE) is most often encountered in patients with congestive heart failure, hepatic and renal failure, and especially in their terminal stages, as an indicator of the decompensation of the patient's condition. Chemical pleurodesis (CP) has been successfully used for several decades in patients with malignant PE, both with primary lesion of the pleura, and with its secondary lesion. The choice of an agent for pleurodesis should be based on its effectiveness, safety and availability. Despite the extensive study of this issue, the search for the ideal pleurosclerosant is still underway. The question of induction of pleurodesis in transudative effusions is all the more poorly understood. CP in our country was previously used only for its malignant nature; antineoplastic agents are traditionally administered intrapleurally. The purpose of this article is to assess the efficacy and feasibility of using betadine as a CP agent for PE in patients with CKD. Material and methods: the study was conducted on 6 patients with confirmed transudative PT in CKD. Results. All six patients (100%) managed to achieve a positive effect in the form of stopping the flow of fluid through the pleural drainage. Conclusion. Pleurodesis using betadine and glucose is an effective and safe method for treating patients with recurrent transudative PE in CKD.
Key words: pleural effusion, betadine, chemical pleurodesis, chronic kidney disease.